The Hygiology Post is presenting information about a company that seems to have much potential to help many people. 2012 may be a pivotal year in determining how helpful the patented technologies may actually be for people.
Senesco Technologies has continued to update information on its web site (https://www.senesco.com/; obtained on 9-10-12). As a matter of disclosure : The author continues to be a current shareholder in the company.
The Senesco Technologies web site ( https://www.senesco.com/newsitem.php?id=259; obtained on 9-10-12) has posted relevant information about its research. Here is an excerpt:
Combining SNS01-T with Bortezomib Significantly Increases Its Effectiveness in Model of Multiple Myeloma
BRIDGEWATER, N.J. (September 10th, 2012) – Senesco Technologies, Inc. (‘Senesco’ or the ‘Company’) (NYSE MKT: SNT) announced today that the combination of bortezomib (the active component of VELCADE® marketed by Millennium, The Takeda Oncology Company) and SNS01-T, the subject of Senesco’s on-going multiple myeloma clinical study, performs significantly better than either treatment alone in mouse xenograft models.
‘We are very pleased to have shown that SNS01-T enhances the ability of bortezomib to inhibit tumor growth in the mouse model and could be a way to lower the dose and reduce the severity of treatment-related side effects of bortezomib ,’ said Leslie J. Browne, Ph.D., President and CEO of Senesco. Dr. Browne added, ‘Since treatment increasingly involves combination therapy, it is important that SNS01-T works well when added to current multiple myeloma drugs.’ ”
The Hygiology Post welcomes feedback from readers as to whether the articles (individually and/or collectively) help fulfill its vision and mission.
Louis DeCola, Jr. © 2012 The Hygiology Post